α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

Simon-Sanchez, 2009, Genome-wide association study reveals genetic risk underlying Parkinson's disease, Nat Genet, 41, 1308, 10.1038/ng.487

Tokuda, 2006, Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease, Biochem Biophys Res Commun, 349, 162, 10.1016/j.bbrc.2006.08.024

Mollenhauer, 2008, Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration, Exp Neurol, 213, 315, 10.1016/j.expneurol.2008.06.004

Ohrfelt, 2009, Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders—a marker of synapse loss?, Neurosci Lett, 450, 332, 10.1016/j.neulet.2008.11.015

Noguchi-Shinohara, 2009, CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease, Brain Res, 1251, 1, 10.1016/j.brainres.2008.11.055

Spies, 2009, Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders, J Alzheimers Dis, 16, 363, 10.3233/JAD-2009-0955

Kasuga, 2010, Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease, J Neurol Neurosurg Psychiatry, 81, 608, 10.1136/jnnp.2009.197483

Hong, 2010, DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease, Brain, 133, 713, 10.1093/brain/awq008

Reesink, 2010, CSF alpha-synuclein does not discriminate dementia with lewy bodies from Alzheimer's disease, J Alzheimers Dis, 22, 87, 10.3233/JAD-2010-100186

Tokuda, 2010, Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease, Neurology, 75, 1766, 10.1212/WNL.0b013e3181fd613b

Mollenhauer, 2010, Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies, Biomark Med, 4, 683, 10.2217/bmm.10.90

Hughes, 2002, The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service, Brain, 125, 861, 10.1093/brain/awf080

Ling, 2010, Does corticobasal degeneration exist? A clinicopathological re-evaluation, Brain, 133, 2045, 10.1093/brain/awq123

Brooks, 2010, Imaging dopamine transporters in Parkinson's disease, Biomark Med, 4, 651, 10.2217/bmm.10.86

Schlossmacher, 2010, Biomarker research in Parkinson's disease: objective measures needed for patient stratification in future cause-directed trials, Biomark Med, 4, 647, 10.2217/bmm.10.93

Schulz-Schaeffer, 2010, The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia, Acta Neuropathol, 120, 131, 10.1007/s00401-010-0711-0

Wiltfang, 2005, Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia, World J Biol Psychiatry, 6, 69, 10.1080/15622970510029786

Gibb, 1988, Accuracy in the clinical diagnosis of parkinsonian syndromes, Postgrad Med J, 64, 345, 10.1136/pgmj.64.751.345

McKeith, 2004, Dementia with Lewy bodies, Lancet Neurol, 3, 19, 10.1016/S1474-4422(03)00619-7

McKhann, 1984, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, 34, 939, 10.1212/WNL.34.7.939

Dubois, 2007, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria, Lancet Neurol, 6, 734, 10.1016/S1474-4422(07)70178-3

Gilman, 2008, Second consensus statement on the diagnosis of multiple system atrophy, Neurology, 71, 670, 10.1212/01.wnl.0000324625.00404.15

Folstein, 1975, “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res, 12, 189, 10.1016/0022-3956(75)90026-6

Lippa, 2007, DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers, Neurology, 68, 812, 10.1212/01.wnl.0000256715.13907.d3

Fazekas, 1987, MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging, Am J Roentgenol, 149, 351, 10.2214/ajr.149.2.351

Relkin, 2005, Diagnosing idiopathic normal-pressure hydrocephalus, Neurosurgery, 57, S4

Litvan, 1996, Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop, Neurology, 47, 1, 10.1212/WNL.47.1.1

Siderowf, 2010, CSF amyloid β 1–42 predicts cognitive decline in Parkinson disease, Neurology, 75, 1055, 10.1212/WNL.0b013e3181f39a78

Fagan, 2006, Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans, Ann Neurol, 59, 512, 10.1002/ana.20730

Scherzer, 2008, GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein, Proc Natl Acad Sci USA, 105, 10907, 10.1073/pnas.0802437105

Blennow, 2010, Cerebrospinal fluid and plasma biomarkers in Alzheimer disease, Nat Rev Neurol, 6, 131, 10.1038/nrneurol.2010.4

Mollenhauer, 2006, Beta-amlyoid 1–42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia, Dement Geriatr Cogn Disord, 22, 200, 10.1159/000094871

Baker, 2007, Peirce, Youden and the receiver operating characteristic curves, Am Stat, 61, 343, 10.1198/000313007X247643

Oertel, 2003

Lewitt, 2008, Levodopa for the treatment of Parkinson's disease, N Engl J Med, 359, 2468, 10.1056/NEJMct0800326

Mattsson, 2010, Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall, Clin Chem Lab Med, 48, 603, 10.1515/CCLM.2010.131

Wenning, 2008, Multiple system atrophy: a primary oligodendrogliopathy, Ann Neurol, 64, 239, 10.1002/ana.21465

Miller, 2005, Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia, J Neural Transm, 112, 1613, 10.1007/s00702-005-0378-1

Desplats, 2009, Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein, Proc Natl Acad Sci USA, 106, 13010, 10.1073/pnas.0903691106

Frasier, 2010, Biomarkers in Parkinson's disease: a funder's perspective, Biomark Med, 4, 723, 10.2217/bmm.10.89

Schwingenschuh, 2010, Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study, Mov Disord, 25, 560, 10.1002/mds.23019

Tomlinson, 2010, Identifying targets in alpha-synuclein metabolism to treat Parkinson's and related disorders, 817